ストックスクリーナーアプリを入手
0.6845
1.29%
0.0087
前日終値:
$0.6758
開ける：
$0.66
24時間の取引高:
72,869
Relative Volume:
0.15
時価総額：
$6.91M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-6.10%
1か月 パフォーマンス:
-6.78%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.6554
$0.6983
1週間の範囲:
$0.65
$0.7325
52週間の値動き範囲:
$0.647
$2.75
Metavia Inc Stock (MTVA) Company Profile
MTVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
0.6845 | 7.35M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
Metavia Inc (MTVA) 最新ニュース
MetaVia Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
MetaVia Completes $10 Million Private Placement - TipRanks
MetaVia launches $10M private placement - MSN
MetaVia secures $10 million in private placement - Investing.com
MetaVia (MTVA) to Raise $10M Through Private Placement | MTVA St - GuruFocus
MetaVia secures $10 million in private placement By Investing.com - Investing.com South Africa
MetaVia announces $10M private placement - TipRanks
MetaVia Inc. announced that it expects to receive $9.995395 million in funding - marketscreener.com
Metavia Announces $10 Million Private Placement Priced At-The-Market Under Nasdaq Rules - marketscreener.com
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules - Eastern Progress
MetaVia Unveils Promising DA-1241 Trial Results - TipRanks
Asian shares get a lift from plans for China-US trade talks, Beijing stimulus moves - WFMZ.com
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025 - PR Newswire
Metavia Presents Data On DA-1241, A GPR119 Agonist, Demonstrating Both Hepatoprotective And Glucose-Regulating Effects In Patients With Presumed MASH, At The EASL Congress 2025 - MENAFN.com
Senate confirms Bisignano to lead Social Security Administration as agency faces DOGE overhaul - WFMZ.com
Trump’s meme coin business racks up fees as buyers jump at the chance for access to the president - WFMZ.com
MetaVia Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MetaVia’s Promising Clinical Trial Results and Future Prospects Drive Buy Rating - TipRanks
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial By Investing.com - Investing.com South Africa
Copper Miner Rallies as Takeover Buzz Sparks Investor Optimism - The Globe and Mail
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025 - Eastern Progress
MetaVia’s DA-1241 shows promise in Phase 2a MASH trial - Investing.com
MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors - insights.citeline.com
MetaVia reports promising obesity drug trial results By Investing.com - Investing.com South Africa
How will MetaVia Inc’s (MTVA) earnings compare to estimates this quarter? - uspostnews.com
RIVN’s Q2 earnings predictions: What the experts say - uspostnews.com
Can Newell Brands Inc (NWL) meet market expectations this quarter? - uspostnews.com
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential - The Malaysian Reserve
MetaVia (MTVA) Advances DA-1726 in Obesity Treatment with Promis - GuruFocus
MetaVia Reports Positive Phase 1 Trial Results - TipRanks
MetaVia (MTVA) Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 - StreetInsider
MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential - marketscreener.com
MetaVia's New GLP-1 Drug Achieves 6.3% Weight Loss in Just 26 Days: Phase 1 Trial Reveals Promising Safety Profile - Stock Titan
Stock Market Recap: MetaVia Inc (MTVA) Concludes at 0.74, a 0.64 Surge/Decline - DWinneX
MetaVia’s (MTVA) Buy Rating Reiterated at HC Wainwright - Defense World
Health Beat: Medical milestone: First drug for sleep apnea - WFMZ.com
MTVA stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
MTVA stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%… - Zacks Small Cap Research
Korean Dental Association forms election planning team to enhance public oral healthCHOSUNBIZ - Chosunbiz
MetaVia’s obesity drug cuts body weight by 6.3% in 26 days in phase 1 - koreabiomed.com
MetaVia reports positive obesity drug trial results By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.39% - Investing.com India
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial - marketscreener.com
Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Smart Shirt Might Predict Heart Problems - WFMZ.com
Metavia Inc (MTVA) 財務データ
Metavia Inc (MTVA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):